Solute carrier family 22 member 5
Details
- Name
- Solute carrier family 22 member 5
- Synonyms
- High-affinity sodium-dependent carnitine cotransporter
- OCTN2
- Organic cation/carnitine transporter 2
- Gene Name
- SLC22A5
- Organism
- Humans
- Amino acid sequence
>lcl|BSEQ0000212|Solute carrier family 22 member 5 MRDYDEVTAFLGEWGPFQRLIFFLLSASIIPNGFTGLSSVFLIATPEHRCRVPDAANLSS AWRNHTVPLRLRDGREVPHSCRRYRLATIANFSALGLEPGRDVDLGQLEQESCLDGWEFS QDVYLSTIVTEWNLVCEDDWKAPLTISLFFVGVLLGSFISGQLSDRFGRKNVLFVTMGMQ TGFSFLQIFSKNFEMFVVLFVLVGMGQISNYVAAFVLGTEILGKSVRIIFSTLGVCIFYA FGYMVLPLFAYFIRDWRMLLVALTMPGVLCVALWWFIPESPRWLISQGRFEEAEVIIRKA AKANGIVVPSTIFDPSELQDLSSKKQQSHNILDLLRTWNIRMVTIMSIMLWMTISVGYFG LSLDTPNLHGDIFVNCFLSAMVEVPAYVLAWLLLQYLPRRYSMATALFLGGSVLLFMQLV PPDLYYLATVLVMVGKFGVTAAFSMVYVYTAELYPTVVRNMGVGVSSTASRLGSILSPYF VYLGAYDRFLPYILMGSLTILTAILTLFLPESFGTPLPDTIDQMLRVKGMKHRKTPSHTR MLKDGQERPTILKSTAF
- Number of residues
- 557
- Molecular Weight
- 62751.08
- Theoretical pI
- 8.04
- GO Classification
- FunctionsATP binding / carnitine transmembrane transporter activity / cation / drug transmembrane transporter activity / PDZ domain binding / quaternary ammonium group transmembrane transporter activity / symporter activityProcessescarnitine metabolic process / carnitine transmembrane transport / carnitine transport / drug transmembrane transport / drug transport / modified amino acid transport / positive regulation of intestinal epithelial structure maintenance / quaternary ammonium group transport / quorum sensing involved in interaction with host / sodium ion transport / sodium-dependent organic cation transport / transmembrane transportComponentsapical plasma membrane / brush border membrane / extracellular exosome / integral component of plasma membrane / plasma membrane
- General Function
- Symporter activity
- Specific Function
- Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium. Also relative uptake activity ratio of carnitine to TEA is 11.3.
- Pfam Domain Function
- Sugar_tr (PF00083)
- Transmembrane Regions
- 21-41 143-163 173-193 198-218 233-253 258-278 342-362 374-394 407-427 431-451 463-483 489-509
- Cellular Location
- Membrane
- Gene sequence
>lcl|BSEQ0009938|Solute carrier family 22 member 5 (SLC22A5) ATGCGGGACTACGACGAGGTGACCGCCTTCCTGGGCGAGTGGGGGCCCTTCCAGCGCCTC ATCTTCTTCCTGCTCAGCGCCAGCATCATCCCCAATGGCTTCACCGGCCTGTCCTCCGTG TTCCTGATAGCGACCCCGGAGCACCGCTGCCGGGTGCCGGACGCCGCGAACCTGAGCAGC GCCTGGCGCAACCACACTGTCCCACTGCGGCTGCGGGACGGCCGCGAGGTGCCCCACAGC TGCCGCCGCTACCGGCTCGCCACCATCGCCAACTTCTCGGCGCTTGGGCTGGAGCCGGGG CGCGACGTGGACCTGGGGCAGCTGGAGCAGGAGAGCTGTCTGGATGGCTGGGAGTTCAGT CAGGACGTCTACCTGTCCACCATTGTGACCGAGCAAGACAGTGGGGCCTACAATGCTATG AAAAACAGGATGGGAAAGAAGCCTGCTCTCTGCCTTCCTGCCCAGTGGAACCTGGTGTGT GAGGACGACTGGAAGGCCCCACTCACAATCTCCTTGTTCTTCGTGGGTGTGCTGTTGGGC TCCTTCATTTCAGGGCAGCTGTCAGACAGGTTTGGCCGGAAGAATGTGCTGTTCGTGACC ATGGGCATGCAGACAGGCTTCAGCTTCCTGCAGATCTTCTCGAAGAATTTTGAGATGTTT GTCGTGCTGTTTGTCCTTGTAGGCATGGGCCAGATCTCCAACTATGTGGCAGCATTTGTC CTGGGGACAGAAATTCTTGGCAAGTCAGTTCGTATAATATTCTCTACGTTAGGAGTGTGC ATATTTTATGCATTTGGCTACATGGTGCTGCCACTGTTTGCTTACTTCATCCGAGACTGG CGGATGCTGCTGGTGGCGCTGACGATGCCGGGGGTGCTATGCGTGGCACTCTGGTGGTTC ATCCCTGAGTCCCCCCGATGGCTCATCTCTCAGGGACGATTTGAAGAGGCAGAGGTGATC ATCCGCAAGGCTGCCAAAGCCAATGGGATTGTTGTGCCTTCCACTATCTTTGACCCGAGT GAGTTACAAGACCTAAGTTCCAAGAAGCAGCAGTCCCACAACATTCTGGATCTGCTTCGA ACCTGGAATATCCGGATGGTCACCATCATGTCCATAATGCTGTGGATGACCATATCAGTG GGCTATTTTGGGCTTTCGCTTGATACTCCTAACTTGCATGGGGACATCTTTGTGAACTGC TTCCTTTCAGCGATGGTTGAAGTCCCAGCATATGTGTTGGCCTGGCTGCTGCTGCAATAT TTGCCCCGGCGCTATTCCATGGCCACTGCCCTCTTCCTGGGTGGCAGTGTCCTTCTCTTC ATGCAGCTGGTACCCCCAGACTTGTATTATTTGGCTACAGTCCTGGTGATGGTGGGCAAG TTTGGAGTCACGGCTGCCTTTTCCATGGTCTACGTGTACACAGCCGAGCTGTATCCCACA GTGGTGAGAAACATGGGTGTGGGAGTCAGCTCCACAGCATCCCGCCTGGGCAGCATCCTG TCTCCCTACTTCGTTTACCTTGGTGCCTACGACCGCTTCCTGCCCTACATTCTCATGGGA AGTCTGACCATCCTGACAGCCATCCTCACCTTGTTTCTCCCAGAGAGCTTCGGTACCCCA CTCCCAGACACCATTGACCAGATGCTAAGAGTCAAAGGAATGAAACACAGAAAAACTCCA AGTCACACAAGGATGTTAAAAGATGGTCAAGAAAGGCCCACAATCCTTAAAAGCACAGCC TTCTAA
- Chromosome Location
- 5
- Locus
- 5q31
- External Identifiers
Resource Link UniProtKB ID O76082 UniProtKB Entry Name S22A5_HUMAN GenBank Protein ID 3273741 GenBank Gene ID AF057164 GenAtlas ID SLC22A5 HGNC ID HGNC:10969 - General References
- Wu X, Prasad PD, Leibach FH, Ganapathy V: cDNA sequence, transport function, and genomic organization of human OCTN2, a new member of the organic cation transporter family. Biochem Biophys Res Commun. 1998 May 29;246(3):589-95. [Article]
- Tamai I, Ohashi R, Nezu J, Yabuuchi H, Oku A, Shimane M, Sai Y, Tsuji A: Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J Biol Chem. 1998 Aug 7;273(32):20378-82. [Article]
- Nezu J, Tamai I, Oku A, Ohashi R, Yabuuchi H, Hashimoto N, Nikaido H, Sai Y, Koizumi A, Shoji Y, Takada G, Matsuishi T, Yoshino M, Kato H, Ohura T, Tsujimoto G, Hayakawa J, Shimane M, Tsuji A: Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter. Nat Genet. 1999 Jan;21(1):91-4. [Article]
- Maekawa S, Mori D, Nishiya T, Takikawa O, Horinouchi T, Nishimoto A, Kajita E, Miwa S: OCTN2VT, a splice variant of OCTN2, does not transport carnitine because of the retention in the endoplasmic reticulum caused by insertion of 24 amino acids in the first extracellular loop of OCTN2. Biochim Biophys Acta. 2007 Jun;1773(6):1000-6. Epub 2007 Apr 19. [Article]
- Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21. [Article]
- Schmutz J, Martin J, Terry A, Couronne O, Grimwood J, Lowry S, Gordon LA, Scott D, Xie G, Huang W, Hellsten U, Tran-Gyamfi M, She X, Prabhakar S, Aerts A, Altherr M, Bajorek E, Black S, Branscomb E, Caoile C, Challacombe JF, Chan YM, Denys M, Detter JC, Escobar J, Flowers D, Fotopulos D, Glavina T, Gomez M, Gonzales E, Goodstein D, Grigoriev I, Groza M, Hammon N, Hawkins T, Haydu L, Israni S, Jett J, Kadner K, Kimball H, Kobayashi A, Lopez F, Lou Y, Martinez D, Medina C, Morgan J, Nandkeshwar R, Noonan JP, Pitluck S, Pollard M, Predki P, Priest J, Ramirez L, Retterer J, Rodriguez A, Rogers S, Salamov A, Salazar A, Thayer N, Tice H, Tsai M, Ustaszewska A, Vo N, Wheeler J, Wu K, Yang J, Dickson M, Cheng JF, Eichler EE, Olsen A, Pennacchio LA, Rokhsar DS, Richardson P, Lucas SM, Myers RM, Rubin EM: The DNA sequence and comparative analysis of human chromosome 5. Nature. 2004 Sep 16;431(7006):268-74. [Article]
- Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7. [Article]
- Wu X, Huang W, Prasad PD, Seth P, Rajan DP, Leibach FH, Chen J, Conway SJ, Ganapathy V: Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter. J Pharmacol Exp Ther. 1999 Sep;290(3):1482-92. [Article]
- Wollscheid B, Bausch-Fluck D, Henderson C, O'Brien R, Bibel M, Schiess R, Aebersold R, Watts JD: Mass-spectrometric identification and relative quantification of N-linked cell surface glycoproteins. Nat Biotechnol. 2009 Apr;27(4):378-86. doi: 10.1038/nbt.1532. Epub 2009 Apr 6. [Article]
- Mayya V, Lundgren DH, Hwang SI, Rezaul K, Wu L, Eng JK, Rodionov V, Han DK: Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal. 2009 Aug 18;2(84):ra46. doi: 10.1126/scisignal.2000007. [Article]
- Burwinkel B, Kreuder J, Schweitzer S, Vorgerd M, Gempel K, Gerbitz KD, Kilimann MW: Carnitine transporter OCTN2 mutations in systemic primary carnitine deficiency: a novel Arg169Gln mutation and a recurrent Arg282ter mutation associated with an unconventional splicing abnormality. Biochem Biophys Res Commun. 1999 Aug 2;261(2):484-7. [Article]
- Vaz FM, Scholte HR, Ruiter J, Hussaarts-Odijk LM, Pereira RR, Schweitzer S, de Klerk JB, Waterham HR, Wanders RJ: Identification of two novel mutations in OCTN2 of three patients with systemic carnitine deficiency. Hum Genet. 1999 Jul-Aug;105(1-2):157-61. [Article]
- Tang NL, Ganapathy V, Wu X, Hui J, Seth P, Yuen PM, Wanders RJ, Fok TF, Hjelm NM: Mutations of OCTN2, an organic cation/carnitine transporter, lead to deficient cellular carnitine uptake in primary carnitine deficiency. Hum Mol Genet. 1999 Apr;8(4):655-60. [Article]
- Koizumi A, Nozaki J, Ohura T, Kayo T, Wada Y, Nezu J, Ohashi R, Tamai I, Shoji Y, Takada G, Kibira S, Matsuishi T, Tsuji A: Genetic epidemiology of the carnitine transporter OCTN2 gene in a Japanese population and phenotypic characterization in Japanese pedigrees with primary systemic carnitine deficiency. Hum Mol Genet. 1999 Nov;8(12):2247-54. [Article]
- Seth P, Wu X, Huang W, Leibach FH, Ganapathy V: Mutations in novel organic cation transporter (OCTN2), an organic cation/carnitine transporter, with differential effects on the organic cation transport function and the carnitine transport function. J Biol Chem. 1999 Nov 19;274(47):33388-92. [Article]
- Mayatepek E, Nezu J, Tamai I, Oku A, Katsura M, Shimane M, Tsuji A: Two novel missense mutations of the OCTN2 gene (W283R and V446F) in a patient with primary systemic carnitine deficiency. Hum Mutat. 2000 Jan;15(1):118. [Article]
- Wang Y, Kelly MA, Cowan TM, Longo N: A missense mutation in the OCTN2 gene associated with residual carnitine transport activity. Hum Mutat. 2000;15(3):238-45. [Article]
- Wang Y, Taroni F, Garavaglia B, Longo N: Functional analysis of mutations in the OCTN2 transporter causing primary carnitine deficiency: lack of genotype-phenotype correlation. Hum Mutat. 2000 Nov;16(5):401-7. [Article]
- Wang Y, Korman SH, Ye J, Gargus JJ, Gutman A, Taroni F, Garavaglia B, Longo N: Phenotype and genotype variation in primary carnitine deficiency. Genet Med. 2001 Nov-Dec;3(6):387-92. [Article]
- Makhseed N, Vallance HD, Potter M, Waters PJ, Wong LT, Lillquist Y, Pasquali M, Amat di San Filippo C, Longo N: Carnitine transporter defect due to a novel mutation in the SLC22A5 gene presenting with peripheral neuropathy. J Inherit Metab Dis. 2004;27(6):778-80. [Article]
- Dobrowolski SF, McKinney JT, Amat di San Filippo C, Giak Sim K, Wilcken B, Longo N: Validation of dye-binding/high-resolution thermal denaturation for the identification of mutations in the SLC22A5 gene. Hum Mutat. 2005 Mar;25(3):306-13. [Article]
- Urban TJ, Gallagher RC, Brown C, Castro RA, Lagpacan LL, Brett CM, Taylor TR, Carlson EJ, Ferrin TE, Burchard EG, Packman S, Giacomini KM: Functional genetic diversity in the high-affinity carnitine transporter OCTN2 (SLC22A5). Mol Pharmacol. 2006 Nov;70(5):1602-11. Epub 2006 Aug 24. [Article]
- Schimmenti LA, Crombez EA, Schwahn BC, Heese BA, Wood TC, Schroer RJ, Bentler K, Cederbaum S, Sarafoglou K, McCann M, Rinaldo P, Matern D, di San Filippo CA, Pasquali M, Berry SA, Longo N: Expanded newborn screening identifies maternal primary carnitine deficiency. Mol Genet Metab. 2007 Apr;90(4):441-5. Epub 2006 Nov 28. [Article]
- El-Hattab AW, Li FY, Shen J, Powell BR, Bawle EV, Adams DJ, Wahl E, Kobori JA, Graham B, Scaglia F, Wong LJ: Maternal systemic primary carnitine deficiency uncovered by newborn screening: clinical, biochemical, and molecular aspects. Genet Med. 2010 Jan;12(1):19-24. doi: 10.1097/GIM.0b013e3181c5e6f7. [Article]
- Li FY, El-Hattab AW, Bawle EV, Boles RG, Schmitt ES, Scaglia F, Wong LJ: Molecular spectrum of SLC22A5 (OCTN2) gene mutations detected in 143 subjects evaluated for systemic carnitine deficiency. Hum Mutat. 2010 Aug;31(8):E1632-51. doi: 10.1002/humu.21311. [Article]
- Lee NC, Tang NL, Chien YH, Chen CA, Lin SJ, Chiu PC, Huang AC, Hwu WL: Diagnoses of newborns and mothers with carnitine uptake defects through newborn screening. Mol Genet Metab. 2010 May;100(1):46-50. doi: 10.1016/j.ymgme.2009.12.015. Epub 2009 Dec 28. [Article]
- Rose EC, di San Filippo CA, Ndukwe Erlingsson UC, Ardon O, Pasquali M, Longo N: Genotype-phenotype correlation in primary carnitine deficiency. Hum Mutat. 2012 Jan;33(1):118-23. doi: 10.1002/humu.21607. Epub 2011 Oct 11. [Article]
Drug Relations
- Drug Relations
DrugBank ID Name Drug group Pharmacological action? Actions Details DB00583 Levocarnitine approved, investigational unknown Details DB01035 Procainamide approved unknown inhibitor Details DB00184 Nicotine approved unknown inhibitor Details DB01577 Metamfetamine approved, illicit, withdrawn unknown inhibitor Details DB00536 Guanidine approved unknown inhibitor Details DB00501 Cimetidine approved, investigational unknown inhibitor Details DB00122 Choline approved, nutraceutical unknown inhibitor Details DB00182 Amphetamine approved, illicit, investigational unknown substrate Details DB01151 Desipramine approved, investigational unknown inhibitor Details DB00661 Verapamil approved unknown inhibitor Details DB00313 Valproic acid approved, investigational unknown inhibitor Details DB01208 Sparfloxacin approved, investigational, withdrawn unknown inhibitor Details DB00468 Quinine approved unknown inhibitor Details DB00908 Quinidine approved, investigational unknown inhibitor Details DB01032 Probenecid approved, investigational unknown inhibitor Details DB00345 Aminohippuric acid approved, investigational unknown inhibitor Details DB01165 Ofloxacin approved unknown inhibitor Details DB01059 Norfloxacin approved unknown inhibitor Details DB00627 Niacin approved, investigational, nutraceutical unknown inhibitor Details DB00978 Lomefloxacin approved, investigational unknown inhibitor Details DB00365 Grepafloxacin approved, investigational, withdrawn unknown inhibitor Details DB00695 Furosemide approved, vet_approved unknown inhibitor Details DB00148 Creatine approved, investigational, nutraceutical unknown inhibitor Details DB00575 Clonidine approved unknown inhibitor Details DB00456 Cefalotin approved, investigational, vet_approved unknown inhibitor Details DB00689 Cephaloglycin approved unknown inhibitor Details DB00125 Arginine investigational, nutraceutical unknown inhibitor Details DB04630 Aldosterone experimental, investigational unknown inhibitor Details DB00970 Dactinomycin approved, investigational unknown inhibitor Details DB01053 Benzylpenicillin approved, vet_approved unknown inhibitor Details DB01000 Cyclacillin approved unknown inhibitor Details DB01333 Cefradine approved unknown inhibitor Details DB00567 Cephalexin approved, investigational, vet_approved unknown inhibitor Details DB00671 Cefixime approved, investigational unknown inhibitor Details DB01413 Cefepime approved, investigational unknown inhibitor Details DB00535 Cefdinir approved unknown inhibitor Details DB01140 Cefadroxil approved, vet_approved, withdrawn unknown inhibitor Details DB00415 Ampicillin approved, vet_approved unknown inhibitor Details DB00152 Thiamine approved, investigational, nutraceutical, vet_approved unknown inhibitor Details DB00368 Norepinephrine approved unknown inhibitor Details DB00281 Lidocaine approved, vet_approved unknown inhibitor Details DB05381 Histamine approved, investigational unknown inhibitor Details DB00988 Dopamine approved unknown inhibitor Details DB01075 Diphenhydramine approved, investigational unknown inhibitor Details DB03128 Acetylcholine approved, investigational unknown inhibitor Details DB00583 Levocarnitine approved, investigational unknown substrate Details DB00332 Ipratropium approved, experimental unknown substrate Details DB01409 Tiotropium approved unknown substrate Details DB08795 Azidocillin experimental unknown inhibitor Details DB08837 Tetraethylammonium experimental, investigational unknown Details DB06691 Mepyramine approved, vet_approved unknown Details DB08842 Acetylcarnitine approved, investigational unknown Details DB04133 Degraded Cephaloridine experimental unknown Details DB14006 Choline salicylate approved, nutraceutical unknown inhibitor Details DB14754 Solriamfetol approved unknown Details DB09237 Levamlodipine approved, investigational unknown inhibitor Details DB00983 Formoterol approved, investigational unknown substrate Details DB06709 Methacholine approved, investigational no inhibitor Details DB00871 Terbutaline approved unknown substrate Details DB00619 Imatinib approved no substrate Details DB01005 Hydroxyurea approved no substrate Details